Skip to content

The influence of white noise and dopamine on language learning in healthy young adults.

The influence of white noise and levodopa on language learning in healthy young adults.

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12620000809932
Enrollment
54
Registered
2020-08-12
Start date
2020-06-02
Completion date
2020-12-02
Last updated
2021-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The aim of this project is to investigate the influence of white noise on auditory and language processing and examine how this influence is modulated by changes in dopamine. More specifically, we will combine the behavioural manipulations of auditory white noise and word learning with the pharmacological manipulation of dopamine, which is the neurotransmitter implicated in learning and attentional processes. Our objective is to quantify the influence of white noise and dopamine by measuring the accuracy of people’s responses for the word-learning tasks as well as using fMRI to measure changes in brain activity while people perform the tasks.

Interventions

Arm 1: Pharmacological manipulation of dopamine (i.e., ingestion of one Madopar tablet of 125mg). Arm 2: No pharmacological manipulation of dopamine (i.e., ingestion of a placebo tablet containing an inactive substance). The intervention drug (i.e., Madopar) will contain two active substances: 100mg of levodopa and 25mg of benserazide. The placebo tablet will contain an inactive substance: 125mg of After ingesting either the Madopar tablet or placebo tablet, participants will be asked to

Arm 1: Pharmacological manipulation of dopamine (i.e., ingestion of one Madopar tablet of 125mg). Arm 2: No pharmacological manipulation of dopamine (i.e., ingestion of a placebo tablet containing an inactive substance). The intervention drug (i.e., Madopar) will contain two active substances: 100mg of levodopa and 25mg of benserazide. The placebo tablet will contain an inactive substance: 125mg of After ingesting either the Madopar tablet or placebo tablet, participants will be asked to complete an in-scanner new word learning task where half of the words (20 out of 40 new words) will be learned with auditory white noise being delivered through headphones (at approximately 70 dB on top of background scanner noise) and half of the words (20 out of 40 new words) will be learned without auditory white noise being delivered (i.e., only background scanner noise). A counterbalanced order will be used, with half of the participants in both arms learning the first block of 20 new words with white noise and the other half of the participants in both arms learning the second block of 20 new words with white noise. The in-scanner new word learning task will take approximately 50 minutes to complete, with the first 25 minutes used to learn the first block of 20 new words (with white noise or not) and the last 25 minutes used to learn the second block of 20 new words (with white noise or not). In both blocks, participants will have 3 exposures to the 20 new words, and after each exposure, participants will complete an in-scanner recognition task to test their learning. All participants will experience all 3 exposures. Each exposure will consist of seeing the 20 new words paired with a picture, one at a time for 5 seconds. Participants will receive $1 for each new word correctly learned. Staff involved in recruitment and delivery of the intervention include a clinical nurse, radiographer, radiologist, speech pathologist, post-doctoral research fellow and research assistant. The intervention session will be conducted at the Herston Imaging Research Facility in Brisbane, Australia.

Sponsors

The University of Queensland
Lead SponsorUniversity

Study design

Allocation
Randomised controlled trial
Intervention model
Other
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
All
Age
18 Years to 35 Years
Healthy volunteers
Yes

Inclusion criteria

The inclusion criteria for this project requires that participants speak English as a first language, are aged between 18 and 35 and are right-handed, have normal or corrected-to-normal vision and/or hearing, are MRI compatible, and can safely be administered a 125 mg dose of Madopar.

Exclusion criteria

The exclusion criteria for this project stipulates that participants will not be able to take part if they have a history of developmental learning or speech-language or other psychiatric disorder, neurological injury or disease, mental illness, currently taking neuroactive drugs for medicinal or recreational purposes (e.g., antidepressants, sedatives, stimulants, analgesics), use of hormone replacement therapy, is currently pregnant, and/or any other reason that might make it unsafe to undergo an MRI.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026